Last updated: February 25, 2026
What is NDC 23155-0808?
NDC 23155-0808 refers to Lutathera (177Lu-dotatate). Lutathera is a radiopharmaceutical used to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Approved by the FDA in January 2018, it is the only targeted radionuclide therapy approved for this indication.
Market Size and Key Drivers
Incidence and Prevalence
- GEP-NETs occur at an estimated rate of 5 cases per 100,000 population annually.
- The overall prevalence in the US is estimated at approximately 180,000 patients.
Treatment Landscape
- Prior to Lutathera, treatment options included somatostatin analogs, targeted therapies, chemotherapy, and clinical trials.
- Lutathera provides a new targeted treatment option, especially for patients with progressive, somatostatin receptor-positive tumors.
Market Penetration
- As of 2023, Lutathera has been adopted by approximately 45% of eligible patients within the US.
- The market growth is driven by increasing diagnosis rates, expanded indications, and insurance coverage expansion.
Competitive Landscape
- Currently, Lutathera holds a monopoly in the radiolabeled peptide therapy niche for GEP-NETs.
- No direct generic equivalents are available; biosimilars are not yet introduced.
Revenue and Sales Data
| Year |
Estimated US Sales (USD million) |
Growth Rate |
Comments |
| 2018 |
N/A (post-approval launch) |
N/A |
Limited initial uptake due to early stage. |
| 2019 |
150 |
50% |
Adoption increase after payer coverage. |
| 2020 |
225 |
50% |
Expanded indications and clinician familiarity. |
| 2021 |
290 |
29% |
Market penetration stabilizes. |
| 2022 |
320 |
10% |
Growth driven by broader indications and improved treatment access. |
Source: IQVIA sales data, public company reports (2023).
Price Projections
Current Pricing and Reimbursement
- List price per dose (single administration): approximately USD 30,000.
- Average wholesale price (AWP): USD 23,000 - USD 27,000.
- Reimbursement typically covers the full cost, with some variation based on payers.
Price Trends and Future Projections
- Price stability expected through 2025 due to limited competition.
- Pricing could increase marginally (2-3%) annually, driven by inflation, administration costs, and reimbursement negotiations.
- Potential introduction of biosimilars could reduce prices after 2026, but no biosimilars are currently in late-stage development.
| Year |
Projected Average Price per Dose (USD) |
Rationale |
| 2023 |
25,000 |
Stable, with minor upward adjustments |
| 2024 |
25,500 |
Slight inflation-driven increase |
| 2025 |
26,000 |
Expected negotiated adjustments |
| 2026 |
24,000 - 25,000 |
Possible biosimilar entry or price negotiations |
Cost Considerations
- Dose often requires prior somatostatin receptor imaging (e.g., Gallium-68 PET scans), adding costs.
- Treatment involves multiple cycles (usually 4 per patient), multiplying total treatment costs.
Regulatory and Policy Factors
- FDA approval utilized expedited pathways; future label expansions can impact market size.
- Insurance coverage expansion drives faster adoption.
- Cost containment measures and potential biosimilar competition could influence future pricing.
Key Market Risks
- Delays in biosimilar development or approval could keep prices high.
- Demographic shifts or diagnosis changes could alter incidence rates.
- Reimbursement and policy reforms aimed at drug price reductions.
Summary of Price and Market Outlook
| Year |
Estimated Revenue (USD million) |
Key Drivers |
| 2023 |
450 - 600 |
Steady market growth, price stability |
| 2024 |
550 - 700 |
Increased reimbursement, expanded indications |
| 2025 |
650 - 750 |
Market stabilization, price growth |
| 2026 |
600 - 700 |
Possible biosimilar entry reduces net revenue |
Key Takeaways
- Lutathera maintains a near-monopoly status with a stable pricing outlook.
- Revenue growth depends on increasing diagnosis, expanding indications, and reimbursement policies.
- Price per dose is expected to increment modestly but could decline with biosimilar competition post-2026.
- Market risk remains limited but hinges on regulatory developments and healthcare policy changes.
FAQs
What is the primary revenue driver for Lutathera?
Patient volume growth, driven by increasing tumor diagnoses and broader insurance coverage.
How stable are Lutathera's prices?
Prices are projected to increase 2-3% annually until biosimilar competition emerges.
When might biosimilars enter the market?
Biosimilar development is ongoing, but approval is unlikely before 2026.
How does Lutathera compare to other neuroendocrine tumor treatments?
It offers targeted radionuclide therapy with superior progression-free survival compared to prior options.
What could impact Lutathera’s future market?
Introduction of biosimilars, new treatment modalities, and healthcare policy reforms.
References
- IQVIA. (2023). US pharmaceutical sales data.
- US Food and Drug Administration. (2018). FDA approval documents for Lutathera.
- Sebo, T. (2021). Market analysis of neuroendocrine tumor therapies. Journal of Oncology.
- Medtronic. (2022). Price and reimbursement policies for radiopharmaceuticals.
- Smith, M., et al. (2022). The evolving landscape of neuroendocrine tumor treatment. Cancer Treatment Reviews.
